Immunopathological effect of whole sonicated Staphylococcus LugdunensisAntigen uploaded with Zinc oxide nanoparticle in male albino Rats

To investigate the effects of Zinc Oxide nanoparticles as adjuvants for inducing immunological responses against Staphylococcus Lugdunensis, fitty A number of healthy white male rats, aged approximately 8-10 weeks, were randomly divided into five groups and subjected to the following treatments. The control negative group, Group 1 (n=10), was infected with 0.3 ml of aseptic normal saline. Group 2 (n=10): infection of rats with Staphylococcus lugdunensis, intra peritoneal (I/P) Challenge Dose of Staphylococcus. Lugdunensis (1.5x108 Cell/ml) was used according (McFarland standards). (control positive group). Group 3 (n=10): was immunized S/C with (0.3ml) of whole sonicated Staphylococcus lugdunensis antigens (3mg/ml) 2dose with 2 weeks interval then infected with Staphylococcus lugdunensis. Group 4 (n=10): was immunized S/C with (0.3ml) of whole sonicated Staphylococcus lugdunensis antigens(3mg/ml) that uploaded on ZnO nanoparticles then 2dose with 2 weeks interval infected with Staphylococcus lugdunensis. Group 5 (n=10): were Injection with (0.3ml) of S/C ZnO-NPs. At 28-day post immunization, and serum was collected for detection of TNF-α, levels. After 30-day post immunization the rats were infected with Staphylococcus lugdunensis Intra peritoneal(I/P) (1.5x108 Cell/ml). Five rats were sacrificed from each group at day 7, and 21 post infection and samples from internal organs (liver and spleen) were taken for histopathology. That show high levels of TNF-α in the 2 nd and 3rd group compared to 1st and 4th groups. the result express focal granulomatous in the liver parenchyma, Hepatocyte Fatty change, necrosis of the hepatocytes, Thrombus in the portal area, in animal at the1st Although animals in the second and third groups showed mild to absent granulomatous lesions, it was determined that vaccinated animals with sonicated Ags containing ZnO-NPs achieve a strong immune response that fully protects against Staphylococcus lugdunensis infection. This is the first step towards developing a vaccination therapy.